Stanford-StartX Fund has supported a $4m round for Imprimed, which is working on precision cancer treatments for dogs.
Imprimed, a US-based precision cancer treatment company, has secured $4m in funding from investors including the Stanford-StartX Fund, the investment vehicle for Stanford University-affiliated accelerator StartX.
Draper Associates led the round, while Murex Partners, Plug & Play Ventures also took part. The total figure includes a previously unannounced $330,000 pre-seed investment led by Plug & Play Ventures.
Imprimed exploits precision medicine technology to help veterinary oncologists identify appropriate chemotherapies for an individual dog. The company is initially focusing on lymphoma.
The company is offering its service free of charge before completing its planned clinical trial. It hopes to help treat more than 500 dogs by 2020.
The funding will support a clinical trial at Sage Veterinary Centers in the San Francisco Bay Area to refine processes and techniques.
Hye Ryeon Lee, co-founder and chief operating officer of Imprimed, said: “Most human and veterinary precision medicine in the cancer field focuses on genomic information to predict drug responses of each patient.
“Genomic data is invaluable, but it is nearly impossible to take into account all the complicated and complex interactions inside the cancer cells solely based on the genetic information. Here at Imprimed, we obtain with functional data to show how each patient’s cancer cells react to various drug treatments, as well as collecting the genomic information.”
